<!DOCTYPE html>
<html lang="en">
    <head>
        <meta name="DC.IDENTIFIER" content="http://dx.doi.org/10.17917/EQCT-3C51" scheme="DCTERMS.UI"><title>caNanoLab DOI Landing page</title>
        <style>
            h1 { text-align: center;}
            h2 { text-align: left;}
            table { border: 1px solid #dddddd; text-align: left; padding: 8px }
            td, th { border: 1px solid #dddddd; text-align: left; padding: 8px }
            tr:nth-child(even) { background-color: #dddddd }
        </style>
    </head><body><img src="./assets/images/crdc-logo.svg" alt="CRDC General Commons Logo"><h1> caNanoLab DOI </h1><hr><p><b>Protocol Type:</b> in vitro assay</p><p><b>Protocol Name:</b> NCL Method ITA-5.2: Analysis of Complement Activation by Single-Plex EIA or Multiplex ELISA</p><p><b>Protocol Abbreviation:</b> ITA-5.2</p><p><b>Protocol Version:</b> 3<hr><p><b>DOI:</b> <a href = http://dx.doi.org/10.17917/EQCT-3C51>http://dx.doi.org/10.17917/EQCT-3C51</a></p><p><b>Protocol File:</b> protocols/20240410_19-17-02-617_NCL_Method_ITA-5.2.pdf<p><b>File Title:</b> ITA-5.2</p><p><b>Description:</b></b> This document describes a protocol for quantitative determination of complement activation by an Enzyme Immunoassay (EIA). human plasma is exposed to a test material and subsequently analyzed by EIA for the presence of the complement components C4d, iC3b and Bb. The antibodies specific to these proteins are immobilized on 96 well plates and are obtained from commercial suppliers.<hr><p><b>Resource Type:</b>  Protocol</p><p><b>Data Access:</b> <a href =https://general.datacommons.cancer.gov/#/data>https://general.datacommons.cancer.gov/#/data</a><p></body></html>